Press release
Investigation announced for Investors who lost money with shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
An investigation for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares over potential securities laws violations.
Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) concerning whether a series of statements by Regeneron Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Tarrytown, NY based Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
On April 10, 2024the Department of Justice filed a lawsuit against Regeneron Pharmaceuticals, Inc. The lawsuit alleges that Regeneron Pharmaceuticals, Inc. failed to disclose millions of dollars in price concessions given to drug distributors in the form of credit card fee reimbursements. According to the lawsuit, this created a higher average selling price for the Company's Eylea product than Medicare allowed for.
Those who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who lost money with shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) here
News-ID: 3540083 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with Hub Group, Inc. (NASDAQ: HUBG) shou …
An investor, who purchased shares of Hub Group, Inc. (NASDAQ: HUBG), filed a lawsuit over alleged violations of Federal Securities Laws by Hub Group, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Hub Group, Inc. (NASDAQ: HUBG) have certain options and for certain investors are short and strict deadlines running. Deadline: August 28, 2026. NASDAQ: HUBG investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Long-Term Investors in ImmunityBio, Inc. (NASDAQ: IB …
An investigation was announced for long-term investors in shares of ImmunityBio, Inc. (NASDAQ: IBRX) concerning potential breaches of fiduciary duties by certain directors of ImmunityBio, Inc.
Investors who are current long term investors in ImmunityBio, Inc. (NASDAQ: IBRX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: IBRX stocks…
Lucid Group, Inc. (NASDAQ: LCID) Investor Alert: Deadline in Lawsuit on July 28, …
A deadline is coming up on July 28, 2026 in the lawsuit filed for certain investors of Lucid Group, Inc. (NASDAQ: LCID) over alleged securities laws violations by Lucid Group, Inc.
Investors who purchased shares of Lucid Group, Inc. (NASDAQ: LCID) have certain options and there are strict and short deadlines running. Deadline: July 28, 2026. Lucid Group, Inc. (NASDAQ: LCID) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Investigation Alert: Long-Term Investors who hold shares of Vital Farms, Inc. (N …
An investigation was announced for current long-term investors in shares of Vital Farms, Inc. (NASDAQ: VITL) concerning potential breaches of fiduciary duties by certain directors of Vital Farms, Inc.
Investors who are current long term investors in Vital Farms, Inc. (NASDAQ: VITL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Regeneron
Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • …
The qualitative latest Research report (2026-2033) on the Block Graft Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
➤ Request a Sample Copy (Complete TOC, Tables…
Myopic macular degeneration Market: Epidemiology, Therapies, Companies, DelveIns …
Myopic macular degeneration therapies, such as EYLEA (aflibercept), VABYSMO (faricimab), and others, are expected to boost the Myopic macular degeneration Market in the upcoming years.
DelveInsight has launched a new report on "Myopic macular degeneration - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myopic macular degeneration, historical and forecasted epidemiology as well as the Myopic macular degeneration market trends in the United States, EU5 (Germany,…
Multiple Myeloma Market on Track for Major Expansion by 2034, According to Delve …
The Key Multiple Myeloma Companies in the market incude - Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharmaceutical, Regeneron Pharmaceuticals, Cartesian Therapeutics, Alliance Foundation Trials, LLC., US Oncology Research, Cartesian Therapeutics, GlaxoSmithKline, Targovax ASA, Janssen Research & Development, AstraZeneca, Celgene, Bristol-Myers Squibb, Pfizer, Ascentage Pharma Group Inc., TeneoOne Inc., Novartis, and others.
The Multiple Myeloma market is expected to surge due to the disease's increasing…
Filariasis Market Outlook Report 2032 | AstraZeneca, GlaxoSmithKline, Sanofi, Re …
DelveInsight's "Filariasis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Filariasis, historical and forecasted epidemiology, as well as the Filariasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Filariasis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Filariasis market size from 2019 to 2032, segmented…
Oral Antiviral Medicine Market Thriving at a Tremendous Growth | MSD, GSK, Regen …
Global Oral Antiviral Medicine Market Growth 2022-2028 , Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider Oral Antiviral Medicine market, and…
Investigation announced for Investors in shares of Regeneron Pharmaceuticals, In …
An investigation was announced concerning potential securities laws violations by Regeneron Pharmaceuticals, Inc. in connection with certain financial statements.
Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Regeneron Pharmaceuticals, Inc. regarding its business, its prospects and its operations were…
